{"entity":{"id":"nct06737731","kind":"trial","name":"A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SHR-1681 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","summary":"A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06737731 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 300 participants planned, started 2025-01-21 and due to reach its primary completion in 2026-11. Interventions recorded: SHR-1681.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06737731","url":"https://clinicaltrials.gov/study/NCT06737731"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06737731","phase":"1/2","setting":"A Phase I/II, Multicenter, Open-Label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1681 for Injection in Patients With Malignant Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":300,"outcomes":[]},"route":"/trials/nct06737731/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}